← Back

PathMaker Neurosystems Inc. announces receipt of Milestone Achievement Program Award, $200,000, from Massachusetts Life Sciences Center

Boston, MA (July 13, 2015) — PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage neuromodulation company developing novel non-invasive systems for the treatment of neuromotor disorders, today announced that it is the recipient of a Milestone Achievement Program (MAP) award from the Massachusetts Life Sciences Center (MLSC). The MAP award, in the amount of $200,000, will enable PathMaker to initiate engineering and development of a clinical-use version of its first product, MyoRegulator™, intended for the treatment of spasticity and muscle tone disorders in patients with neuromotor dysfunction.

“The PathMaker team is honored to have been recognized with the MAP award,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. “The support of the MLSC MAP program will enable us to finance critical activities needed in preparation for human clinical trials. The MLSC has developed an internationally-recognized model for catalyzing innovation that has been instrumental to the success of numerous life science companies based in the Commonwealth.”

PathMaker Neurosystems Inc. was founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. tsDCS is a novel modality for non-invasive neuromodulation that has only emerged within the last five years, being driven by fundamentally new understandings of spinal circuit biology made by PathMaker’s scientific advisors and their clinical work in treating patients with paralysis, muscle weakness and muscle tone disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.

The Massachusetts Life Sciences Center (MLSC) is a quasi-governmental investment agency that supports life sciences innovation, research, development and commercialization. “We are pleased to be able to facilitate the efforts of PathMaker Neurosystems, an innovative neuromodulation company headquartered in Boston, Massachusetts,” said Pamela Norton, Vice President for Industry Relations and Programs at the MLSC. “We look forward to working with PathMaker as they advance a new generation of non-invasive technology for treating patients with neuromotor conditions.”

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release.

About PathMaker Neurosystems Inc.

PathMaker Neurosystems Inc. is a clinical-stage neuromodulation company founded to commercialize recent breakthrough advances in the development and clinical application of trans-spinal direct current stimulation (tsDCS) for patients with neuromotor disorders. More than 27 million patients in the US and Europe suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders, and the breakthrough non-invasive technology that PathMaker is developing promises to open up entirely new methods of treating these patients.

Press Contact: Don Goncalves, Tiziani Whitmyre, 781.793.9380, dgoncalves@tizinc.com

About Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation’s most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit www.masslifesciences.com.